Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798358

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798358

Brukinsa

PUBLISHED:
PAGES: 271 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Brukinsa Market to Reach US$776.8 Million by 2030

The global market for Brukinsa estimated at US$615.9 Million in the year 2024, is expected to reach US$776.8 Million by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Acute Lymphocytic Leukemia, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$516.7 Million by the end of the analysis period. Growth in the Chronic Lymphocytic Leukemia segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$167.8 Million While China is Forecast to Grow at 7.1% CAGR

The Brukinsa market in the U.S. is estimated at US$167.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$156.5 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Brukinsa Market - Key Trends & Drivers Summarized

Why Has Brukinsa Become a Game-Changer in the Treatment of Hematologic Malignancies?

Brukinsa, a next-generation Bruton's tyrosine kinase (BTK) inhibitor developed by BeiGene, has rapidly emerged as a pivotal therapy in the landscape of hematologic cancers, particularly for patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenstrom’s macroglobulinemia (WM). Its high selectivity for BTK and ability to effectively inhibit B-cell receptor signaling pathways make it a critical weapon against B-cell malignancies. What sets Brukinsa apart is its favorable pharmacokinetic profile, marked by increased target occupancy and improved tissue penetration, which leads to enhanced efficacy and fewer off-target side effects compared to earlier BTK inhibitors like ibrutinib. It also demonstrates a lower incidence of treatment-limiting adverse events such as atrial fibrillation and bleeding, which makes it more tolerable, especially for elderly or high-risk patients. Brukinsa has gained multiple regulatory approvals in the United States, China, and the European Union based on strong clinical trial outcomes, including higher response rates and improved progression-free survival in relapsed or refractory patients. As more data continues to emerge from head-to-head comparison trials, its role in frontline treatment is also gaining attention. The growing recognition of Brukinsa's value by oncologists and its inclusion in various clinical guidelines underscore its importance in redefining standard-of-care practices for a range of blood cancers where targeted therapies are rapidly replacing conventional chemotherapy.

How Are Clinical Trial Outcomes and Regulatory Approvals Driving Brukinsa’s Global Expansion?

The clinical success of Brukinsa has been instrumental in securing widespread regulatory approvals and positioning the drug as a frontrunner in the BTK inhibitor market. Several pivotal clinical trials, including the ASPEN and ALPINE studies, have shown Brukinsa to be not only effective but also better tolerated than its competitors. In the ALPINE trial, for instance, Brukinsa demonstrated superior overall response rates and significantly fewer cardiac side effects compared to ibrutinib in patients with relapsed or refractory CLL. These compelling results led to Brukinsa receiving accelerated approval from the U.S. Food and Drug Administration (FDA) for various indications, with continued evaluation under the agency’s Real-Time Oncology Review (RTOR) and Project Orbis programs, which expedite the review process for promising cancer therapies. Similarly, regulatory bodies in the European Union and China have recognized the potential of Brukinsa, enabling BeiGene to expand access to a broader international patient base. The approvals are not limited to a single type of blood cancer, but span multiple B-cell malignancies, enhancing the drug’s versatility and market footprint. The ability of Brukinsa to meet or exceed key clinical endpoints, including duration of response and progression-free survival, has earned it an expanding role in treatment protocols. These outcomes are increasingly influencing reimbursement decisions by insurers and inclusion in formularies, further supporting its commercial adoption across healthcare systems worldwide. The consistency of clinical data across diverse patient populations and geographical regions strengthens its case as a global standard in targeted oncology treatment.

What Market and Industry Trends Are Supporting the Commercial Success of Brukinsa?

Several key market and industry dynamics are converging to support the strong commercial trajectory of Brukinsa in the oncology therapeutics space. First, the global shift toward targeted therapies in oncology is creating a favorable environment for precision medicines like Brukinsa that offer superior efficacy and safety over traditional chemotherapeutic regimens. Physicians and patients alike are seeking treatment options that not only prolong survival but also offer improved quality of life, especially in chronic conditions like CLL that require long-term therapy. Second, the increasing prevalence of hematologic malignancies due to aging populations and improved diagnostic capabilities is expanding the addressable market. In addition, BeiGene’s aggressive commercialization strategy, including strategic partnerships and market entry into the U.S., Europe, and key Asian markets, has allowed for accelerated geographic penetration. The company’s vertically integrated model, with in-house research, manufacturing, and distribution capabilities, gives it cost and supply chain advantages. Moreover, payers and healthcare systems are becoming more receptive to reimbursing novel oncology therapies with strong clinical value, which bodes well for Brukinsa’s uptake. The drug’s ongoing label expansions and trials in new indications, such as marginal zone lymphoma and follicular lymphoma, further enhance its commercial potential. As competition in the BTK inhibitor space intensifies, Brukinsa’s differentiation based on safety, tolerability, and real-world performance will remain a cornerstone of its market advantage. These combined trends are establishing a robust growth pathway for Brukinsa, reinforcing its place in the expanding oncology therapeutics market.

What Are the Core Drivers Behind Brukinsa’s Rising Adoption and Market Penetration?

The growth in the Brukinsa market is driven by several interconnected clinical, commercial, and strategic factors. Foremost among these is its superior safety and tolerability profile, which is proving critical in both first-line and relapsed or refractory treatment settings where long-term adherence is essential. Its demonstrated ability to reduce common side effects seen with earlier-generation BTK inhibitors is significantly influencing prescribing decisions among hematologists. Another key driver is the rising incidence of B-cell malignancies, such as CLL, MCL, and WM, which are increasing due to aging populations and improved detection practices globally. This trend is expanding the eligible patient population for BTK inhibitors, providing a wider base for Brukinsa adoption. Regulatory momentum, including priority reviews, fast-track designations, and international approvals, is accelerating time-to-market and facilitating broader geographic access. Reimbursement wins and inclusion in national treatment guidelines are also enabling faster adoption, particularly in systems where coverage determines therapeutic choices. BeiGene’s strategic investments in sales force expansion, direct physician engagement, and education initiatives have effectively raised awareness and acceptance of Brukinsa among oncology care providers. Additionally, ongoing clinical trials exploring Brukinsa in combination therapies or in novel indications are poised to unlock further market potential. As personalized medicine continues to gain traction, Brukinsa’s ability to deliver targeted, tolerable, and effective outcomes is ensuring it plays an increasingly central role in modern oncology care. These multifaceted drivers are collectively cementing Brukinsa’s reputation as a transformative solution in hematologic cancer treatment worldwide.

SCOPE OF STUDY:

The report analyzes the Brukinsa market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia); End-User (Hospitals End-User, Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • InnoCare Pharma
  • Janssen Pharmaceuticals (J&J)
  • Lilly Asia Ventures
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pharmacyclics LLC (an AbbVie Co.)
  • Sanofi S.A.
  • Seagen Inc.
  • TG Therapeutics
  • Xynomic Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38586

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Brukinsa - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of B-Cell Malignancies Throws the Spotlight on Brukinsa as a Targeted Therapy Option
    • Here's the Story: How Brukinsa's Selectivity and Tolerability Differentiate It in the BTK Inhibitor Class
    • Expansion of Approved Indications Strengthens Business Case for Wider Adoption Across Hematologic Cancers
    • Growing Use in Treatment-Naive and Relapsed / Refractory Settings Expands Addressable Patient Population
    • Increasing Physician Familiarity and Prescribing Comfort Drives Uptake in Competitive Oncology Markets
    • Rising Demand for Oral Oncologics Supports Continued Momentum in Patient-Centered Treatment Models
    • Growing Head-to-Head Data Against Ibrutinib Throws the Spotlight on Brukinsa's Potential for Market Share Gains
    • Emerging Use in Combination Regimens Generates New Opportunities in Frontline and Maintenance Therapies
    • Increased Adoption in Community Oncology Settings Sustains Prescription Growth Outside Academic Centers
    • Competitive Pressures from Next-Generation BTK Inhibitors Create Urgency for Continued Label Expansion and Differentiation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Brukinsa Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Brukinsa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Brukinsa by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Brukinsa by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Brukinsa by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Brukinsa by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Brukinsa by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Brukinsa by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Brukinsa Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Brukinsa by Disease Type - Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Brukinsa by Disease Type - Percentage Breakdown of Value Sales for Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Brukinsa by End-user - Hospitals End-User, Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Brukinsa by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!